Stereotactic radiosurgery offered results comparable to surgery in controlling local brain metastases, Fox Chase Cancer Center researchers have found.
A phase Ib clinical trial suggests that administering a concentrated dose of anti-CEA CAR-T cells precisely at the site of a solid tumor by means of TriSalus Life Sciences' unique Pressure-enabled Drug Delivery is safe, with encouraging clinical responses.
Nearly four in 10 Americans believe cancer can be cured solely through alternative therapies, according to the American Society of Clinical Oncology's second annual National Cancer Opinion Survey.
Research in the October 2018 issue of JNCCN—Journal of the National Comprehensive Cancer Network--identifies risk factors for chemotherapy-induced febrile neutropenia.
Merck announced the first presentation of interim data from the pivotal phase III KEYNOTE-048 trial investigating Keytruda as both monotherapy and in combination with chemotherapy for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Merck announced the first presentation of results from an interim analysis of KEYNOTE-057, a phase II trial evaluating Keytruda (pembrolizumab) for previously treated patients with high-risk non-muscle invasive bladder cancer with carcinoma in situ or CIS plus papillary disease (Cohort A).
Loxo Oncology Inc. and Bayer AG announced updated clinical data for larotrectinib, an investigational oral, selective, and CNS-active TRK inhibitor, in adult and pediatric patients with TRK fusion cancers.
Pfizer Inc. announced detailed overall survival data from the PALOMA-3 trial, which evaluated Ibrance (palbociclib) in combination with fulvestrant compared to placebo plus fulvestrant in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer whose disease progressed on or after prior endocrine therapy.
Soligenix Inc. said it has received a positive recommendation from the independent Data Monitoring Committee to continue enrolling into the company's phase III “Fluorescent Light Activated Synthetic Hypericin” study for SGX301 (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma.
Merck announced the first presentation of preliminary data from a phase I clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.
